STOCK TITAN

Senti Bioscience Stock Price, News & Analysis

SNTI Nasdaq

Welcome to our dedicated page for Senti Bioscience news (Ticker: SNTI), a resource for investors and traders seeking the latest updates and insights on Senti Bioscience stock.

Senti Biosciences, Inc. (SNTI) is a clinical-stage biotechnology company pioneering gene circuit-engineered cell therapies for cancer treatment. This page serves as the definitive source for corporate announcements, clinical trial updates, and scientific advancements related to their synthetic biology platform.

Investors and researchers will find timely updates on SNTI's CAR-NK cell therapy programs targeting hematologic malignancies and solid tumors. The resource consolidates press releases covering clinical milestones, strategic collaborations, and regulatory developments while explaining complex biotechnological concepts in accessible language.

Key content includes updates on lead programs for acute myeloid leukemia (AML) and hepatocellular carcinoma (HCC), partnership announcements with biopharma innovators, and progress reports on their logic-gated Gene Circuit technology platform. All materials maintain rigorous adherence to factual reporting of verifiable company developments.

Bookmark this page for structured access to SNTI's latest scientific presentations, manufacturing updates, and peer-reviewed research findings. Check regularly for authoritative information directly from corporate communications and verified media sources.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
none
Rhea-AI Summary

Senti Biosciences (SNTI) presented promising preclinical data on its SENTI-202 CAR-NK cell therapy at the AACR Annual Meeting. This therapy targets CD33 and/or FLT3 for treating hematologic malignancies, showing enhanced cytotoxic activity and safety in in vitro and in vivo models. The company aims to submit an IND application by the second half of 2023, focusing on relapsed/refractory patients. Data on SENTI-301A further demonstrated CAR-NK cells' ability to improve persistence and anti-tumor efficacy. Overall, Senti Bio aims to revolutionize treatment for both liquid and solid tumors through its innovative gene circuit technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.54%
Tags

FAQ

What is the current stock price of Senti Bioscience (SNTI)?

The current stock price of Senti Bioscience (SNTI) is $1.44 as of October 1, 2025.

What is the market cap of Senti Bioscience (SNTI)?

The market cap of Senti Bioscience (SNTI) is approximately 36.9M.
Senti Bioscience

Nasdaq:SNTI

SNTI Rankings

SNTI Stock Data

36.89M
11.24M
57.04%
25.76%
0.92%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO